Advances in targeting cyclic nucleotide phosphodiesterases
DH Maurice, H Ke, F Ahmad, Y Wang… - Nature reviews Drug …, 2014 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and
cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides …
cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides …
Clinical and molecular genetics of the phosphodiesterases (PDEs)
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function
Mitochondrial activity is controlled by proteins encoded by both nuclear and mitochondrial
DNA. Here, we identify Sirt7 as a crucial regulator of mitochondrial homeostasis. Sirt7 …
DNA. Here, we identify Sirt7 as a crucial regulator of mitochondrial homeostasis. Sirt7 …
Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth
Background: Anthracyclines, such as doxorubicin (DOX), are potent anticancer agents for
the treatment of solid tumors and hematologic malignancies. However, their clinical use is …
the treatment of solid tumors and hematologic malignancies. However, their clinical use is …
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
R Kamel, J Leroy, G Vandecasteele… - Nature Reviews …, 2023 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …
The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors
Abstract The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating
levels of the second messenger cAMP. Consequently, PDE4 inhibitors have been …
levels of the second messenger cAMP. Consequently, PDE4 inhibitors have been …
Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases
F Vinchi, L De Franceschi, A Ghigo, T Townes… - Circulation, 2013 - Am Heart Assoc
Background—Hemolytic diseases are characterized by enhanced intravascular hemolysis
resulting in heme-catalyzed reactive oxygen species generation, which leads to endothelial …
resulting in heme-catalyzed reactive oxygen species generation, which leads to endothelial …
PI3K and calcium signaling in cardiovascular disease
Receptor signaling relays on intracellular events amplified by secondary and tertiary
messenger molecules. In cardiomyocytes and smooth muscle cells, cyclic AMP (cAMP) and …
messenger molecules. In cardiomyocytes and smooth muscle cells, cyclic AMP (cAMP) and …
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
F Ahmad, T Murata, K Shimizu, E Degerman… - Oral …, 2015 - Wiley Online Library
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their …
monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their …
Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction
Q Wang, Y Liu, Q Fu, B Xu, Y Zhang, S Kim, R Tan… - Circulation, 2017 - Am Heart Assoc
Background: Type 2 diabetes mellitus (DM) and obesity independently increase the risk of
heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia …
heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia …